Skip to main content

Therapeutic development of mesothelin antibody-drug conjugate anetumab ravtansine in mesothelin expressing childhood AML

Douglas Hawkins

Douglas Hawkins

MD

The Children's Hospital of Philadelphia

Project Term: December 1, 2017 - November 30, 2021

We propose to evaluate clinical and pre-clinical utility of mesothelin directed antibody-drug conjugate anetumab ravtansine in childhood AML. Clinical development and pre-clinical assessment of this agent’s efficacy will be conducted in parallel to facilitate timely transition of this agent to children with relapsed AML.

Program
Special Grants
Grant Subprogram
Special TRP
To All Projects